Kendall Capital Management Takes $1.26 Million Position in Collegium Pharmaceutical, Inc. $COLL

Kendall Capital Management bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 34,730 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,257,000.

Other institutional investors have also modified their holdings of the company. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd raised its position in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently issued reports on COLL shares. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Barclays dropped their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Piper Sandler restated a “neutral” rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $27.11 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $882.70 million, a price-to-earnings ratio of 21.86 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a twelve month low of $25.47 and a twelve month high of $50.79. The business has a 50 day simple moving average of $33.67 and a 200-day simple moving average of $35.78.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.68 earnings per share. As a group, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.